Gyre Therapeutics (GYRE) FCF Margin Growth (3y) (2013 - 2026)
Gyre Therapeutics (GYRE) FCF Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -1,272.00 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -2,228.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9,545.00 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -7.75 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -3,088.00 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4,612.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 14,060.00 |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | -6,545.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6,545.00 |
| Mar 31, 2026 | -2,138.00 |
| Dec 31, 2025 | -5,709.00 |
| Mar 31, 2025 | 151,649.00 |
| Dec 31, 2024 | 72,622.00 |
| Sep 30, 2024 | 96,499.00 |
| Jun 30, 2024 | 175,010.00 |
| Mar 31, 2024 | 167,002.00 |
| Dec 31, 2023 | 109,264.00 |
| Sep 30, 2023 | 149,600.00 |
| Jun 30, 2023 | 92,088.00 |
| Mar 31, 2023 | 6,417.00 |
| Mar 31, 2021 | 8.68 Mn |
| Dec 31, 2020 | 90,394.00 |
| Sep 30, 2020 | 7,150.00 |
| Jun 30, 2020 | 305,189.00 |
| Mar 31, 2020 | 155,550.00 |
| Mar 31, 2018 | -8.80 Mn |
| Dec 31, 2017 | -168,637.00 |
| Sep 30, 2017 | -510,192.00 |